Insider Buying: Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Major Shareholder Buys 309,847 Shares of Stock

Aldeyra Therapeutics, Inc (NASDAQ:ALDXGet Free Report) major shareholder Perceptive Advisors Llc bought 309,847 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The stock was purchased at an average price of $4.09 per share, with a total value of $1,267,274.23. Following the transaction, the insider now owns 9,097,858 shares in the company, valued at approximately $37,210,239.22. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Perceptive Advisors Llc also recently made the following trade(s):

  • On Monday, April 1st, Perceptive Advisors Llc acquired 8,374 shares of Aldeyra Therapeutics stock. The shares were purchased at an average price of $3.25 per share, for a total transaction of $27,215.50.

Aldeyra Therapeutics Stock Performance

Shares of ALDX opened at $4.15 on Thursday. The firm has a fifty day moving average of $3.34 and a 200-day moving average of $3.42. The company has a market cap of $244.44 million, a price-to-earnings ratio of -6.48 and a beta of 1.51. Aldeyra Therapeutics, Inc has a 1 year low of $1.42 and a 1 year high of $11.97.

Aldeyra Therapeutics (NASDAQ:ALDXGet Free Report) last posted its earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.13. Analysts predict that Aldeyra Therapeutics, Inc will post -0.26 EPS for the current year.

Wall Street Analysts Forecast Growth

ALDX has been the topic of a number of research reports. StockNews.com raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, January 29th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a research note on Tuesday. Finally, Oppenheimer upgraded Aldeyra Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research note on Wednesday.

Check Out Our Latest Research Report on ALDX

Hedge Funds Weigh In On Aldeyra Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. acquired a new position in Aldeyra Therapeutics during the 2nd quarter worth $32,000. Prime Capital Investment Advisors LLC bought a new position in Aldeyra Therapeutics in the 4th quarter valued at about $35,000. Tower Research Capital LLC TRC increased its stake in Aldeyra Therapeutics by 47,866.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,317 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 4,308 shares during the period. SG Americas Securities LLC bought a new stake in shares of Aldeyra Therapeutics during the 4th quarter worth about $39,000. Finally, NorthRock Partners LLC acquired a new stake in shares of Aldeyra Therapeutics in the 4th quarter worth approximately $42,000. 59.71% of the stock is owned by institutional investors.

Aldeyra Therapeutics Company Profile

(Get Free Report)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

See Also

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.